Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia-Reference-Cited by-同舟云学术

Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia

Published:2015-04 Issue:4 Volume:39 Page:411-418
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Lee Sung-Eun,Choi Soo Young,Oh Yun Jeong,Kim Soo-Hyun,Song Hye-Young,Yoo Hea-Lyun,Lee Mi-Young,Chae Moon-Jung,Kang Ki-Hoon,Hwang Hee-Jeong,Jang Eun-Jung,Kim Dong-Wook

Funder

Ministry of Health & Welfare, Republic of Korea

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference22 articles.

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N Engl J Med,2003

2. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS);Hughes;Blood,2010

3. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors;Marin;J Clinic Oncol,2012

4. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML);Hanfstein;Leukemia,2012

5. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia;Leukemia Research;2022-01

2. Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2019-07

3. BCR-ABL1transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors;Cancer Medicine;2018-08-31

4. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance;Blood Cancer Journal;2018-06-15

5. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia;Clinical Cancer Research;2017-09-22